Cough
Richard M. Kravitz
INTRODUCTION
Cough is one of the most common presenting symptoms in children. The duration of the symptoms determines the level of concern and degree of workup that is warranted. An acute cough, lasting <3 weeks, is frequently related to an infectious illness and is often self-limited. This chapter is concerned with chronic cough, a cough that persists for ≥3 weeks and suggests a potentially more serious underlying cause. A cough has three components. First, there is an inspiratory phase, when the patient takes a deep breath. The inspiratory phase is followed by closure of the glottis and contraction of the expiratory muscles. During this phase, intrathoracic pressure increases. Finally, the glottis opens, allowing the previously inspired air to be expelled at a high velocity (about 60 to 70 mph). The function of coughing is to shake irritants loose from the airway mucosa and move them proximally (if the irritant is located distally) or expel them (if the irritant is located proximally).
DIFFERENTIAL DIAGNOSIS LIST
Infectious Causes
Bacterial Infection
Bacterial pneumonia
Sinusitis
Tuberculosis (TB)
Pertussis
Chlamydia infection
Mycoplasma infection
Viral Infection
Upper respiratory tract infection
Viral pneumonia
Bronchiolitis—respiratory syncytial virus infection, parainfluenza infection
Croup
Influenza
Fungal Infection
Aspergillosis
Allergic bronchopulmonary aspergillosis
Histoplasmosis
Coccidioidomycosis
Toxic (Irritant) Causes
Cigarette smoke
Industrial pollutants
Wood-burning stoves
Cleaning solvents
Perfumes/colognes
Congenital Causes
Pulmonary Malformations
Bronchogenic cysts
Cystic adenomatoid malformation
Congenital lobar emphysema
Pulmonary sequestration
Vascular Malformations
Aberrant innominate artery
Double aortic arch
Airway hemangiomas
Gastrointestinal Malformations
Esophageal duplications
Tracheoesophageal fistula
Genetic Causes
Cystic fibrosis
Immotile cilia syndrome
Inflammatory Causes
Asthma
Allergies
Sarcoidosis
Psychosocial Causes
Psychogenic (habitual) cough
Paradoxical vocal cord dysfunction
Miscellaneous Causes
Pulmonary Disorders
Bronchopulmonary dysplasia
Laryngotracheobronchomalacia
Foreign body in airway
Bronchiectasis
Ears, Nose, and Throat Disorders
Foreign body in the nose or ear canal
Postnasal drip
Middle ear effusion
Paralyzed vocal cord
Swallowing dysfunction with secondary aspiration
Cardiovascular Disorders
Congestive heart failure
Pulmonary edema
Gastrointestinal Disorders
Gastroesophageal reflux disease (GERD) with or without secondary aspiration
Diaphragmatic or subdiaphragmatic mass
Foreign body in the esophagus
Immunologic Disorders
Congenital immunodeficiency with a secondary infection
Medications
Beta-blockers (e.g., propanolol)
Angiotensin-converting enzyme (ACE) inhibitors (e.g., captopril, enalapril, lisinopril)
DIFFERENTIAL DIAGNOSIS DISCUSSION
Asthma
Asthma, the most common chronic illness in children, affects 5% to 10% of children in the United States.
Etiology
The underlying cause of asthma is unknown, although airway inflammation is known to be a major component. The triad of airway inflammation, smooth muscle hyperreactivity, and reversible airway obstruction is characteristic for patients with asthma.
Numerous triggers can precipitate an asthma flare-up, including viral upper respiratory tract infections, sinus infections, exercise, exposure to cold air, weather changes, exposure to allergens (e.g., dust, cockroaches, animal dander, pollen, grass, mold, or certain foods such as shellfish or peanuts), exposure to strong odors (e.g., cigarette smoke, strong chemicals, perfumes), and emotional states (e.g., fear, laughing, crying).
Clinical Features
Asthma symptoms are secondary to airway obstruction brought about by airway inflammation and mucus production and/or increased airway resistance from bronchospasm. Wheezing is the classic presentation of asthma, but other symptoms include chronic coughing (often referred to as cough-variant asthma), shortness of breath, and chest pain or tightness.
Evaluation
A detailed history and physical examination are integral to making the diagnosis of asthma. Wheezing, rhonchi, coarse or decreased breath sounds, or a prolonged expiratory phase may be noted on pulmonary examination. Lung sounds can also be entirely normal at the time of examination, even in patients with a significant history.
Spirometry with a bronchodilator response is used to assess for asthma. In patients with asthma, an obstructive pattern with post-bronchodilator improvement in lung function is frequently seen. If spirometry is not available, a handheld peak-flow meter can be substituted.
HINT: Pulmonary function testing can be normal in many patients with asthma. If asthma is strongly suspected in spite of normal results on pulmonary function testing, then provocational testing (e.g., exercise testing, methacholine challenge) may be indicated to help document airway hyperreactivity. Exercise testing is specific in patients with exercise-induced asthma, whereas the more sensitive methacholine challenge can detect more subtle degrees of airway hyperreactivity.
Treatment
Proper treatment of asthma entails both pharmacologic and nonpharmacologic modalities. For most patients with asthma, ideal therapy includes the use of a daily anti-inflammatory medication along with a rescue bronchodilator given on an as needed basis to treat breakthrough symptoms. Short bursts of oral steroids are often helpful for treating acute flare-ups of asthma, although the side effects of long-term use preclude their use as a chronic maintenance medication (though in severe cases, chronic daily or every other day oral steroids may be needed to adequately control symptoms).
Anti-inflammatory medications include mast cell stabilizers (e.g., cromolyn sodium, nedocromil calcium), inhaled steroids (e.g., beclomethasone, fluticasone, budesonide, ciclesonide, mometasone), and leukotriene inhibitors (e.g., zileuton, zafirlukast, montelukast).
Bronchodilators. β2-agonists (e.g., albuterol, levalbuterol, terbutaline, pirbuterol) are the most effective and commonly used bronchodilators for rescue therapy. Long acting β2-agonists (e.g., salmeterol, formoterol) may be used in combination with inhaled steroids (e.g., Advair®-salmeterol+fluticasone; Symbicort®- formoterol+budesonide, Dulera®-formoterol+mometasone) to provide improved symptom control and pulmonary function values when inhaled steroids alone prove insufficient at controlling the patient’s asthma (of note, these long acting beta agonists should never be used as monodrug therapy when treating asthma). Methylxanthine derivatives (e.g., theophylline) and parasympathetic antagonists (e.g., atropine, ipratropium) may also be used (although they are not routinely used in children).
Nonpharmacologic management entails patient education (to improve self-management), environmental control and prevention skills (to decrease exposure to asthmatic triggers and the likelihood of developing an asthma attack), and home monitoring with a peak-flow monitor (to objectively assess pulmonary status so that appropriate interventions can be instituted and their effects assessed).
Cystic Fibrosis
Etiology
An autosomal recessive disorder, cystic fibrosis is the most common genetic disease affecting whites. The gene is located on chromosome number 7 and codes for a transmembrane protein (cystic fibrosis transmembrane conductance regulator (CFTR)-protein) that functions as a chloride channel. The most common abnormality is an amino acid defect consisting of the deletion of a phenylalanine (the delta F508 mutation).The disease is characterized by multiorgan involvement. Chronic sinopulmonary infections (facilitated by excess altered mucus production in the respiratory tract), pancreatic insufficiency, and abnormalities of the exocrine glands and reproductive tract are major manifestations. In the lungs, dry, thickened secretions hinder clearance of pulmonary secretions. Impaired airway clearance, in combination with abnormal colonization with organisms (e.g., Staphylococcus aureus, Pseudomonas aeruginosa), leads to the development of bronchiectasis and permanent lung damage.
Clinical Features
Major symptoms include a chronic, productive cough, yellow-green sputum, chest congestion, hemoptysis, steatorrhea, poor weight gain, failure to thrive, and meconium ileus or meconium ileus equivalent (intestinal obstruction).
Evaluation
A detailed family history should be obtained as well as growth patterns and stool characteristics. Cardinal features noted on physical examination may include tachypnea, retractions, bronchial breath sounds, wheezes, crackles, a prolonged expiratory phase, nasal polyps, upper airway congestion, digital clubbing, reduced height and weight, rectal prolapse, and hepatomegaly and splenomegaly.
The following laboratory studies are indicated:
Chloride sweat test. Pilocarpine is used to stimulate sweat collection. The sweat chloride level is considered to be elevated if ≥60 mEq/L.
Sputum culture. P. aeruginosa and S. aureus are the bacterial pathogens most often responsible for the chronic sinopulmonary infections. Other organisms, such as Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans, are also seen and tend to be more resistant to therapy.
Complete blood cell (CBC) count. A CBC should be obtained to rule out anemia and to assess for leukocytosis. Hypersplenism has also been reported (evidenced by leukopenia and thrombocytopenia).
Liver function tests are ordered to assess for hepatobiliary disease and obstruction.
Prothrombin time (PT). A PT should be obtained to assess vitamin K sufficiency.
Vitamin A, E, and D levels should be measured to assess for possible fat-soluble vitamin deficiency.
Fecal fat analysis. A 72-hour stool collection should be obtained to assess the degree of pancreatic insufficiency. Fecal elastase may also be measured.
Oxygen saturation analysis and pulmonary function tests should be performed to assess the degree of pulmonary involvement (arterial blood gas analysis is not necessary in most cases).
Genetic testing is indicated. More than 70% of patients have the delta F508 mutation.
HINT: Newborn screening is now available in most states. Only the most common CFTR mutations, however, are tested, so it is possible that patients with the less common alleles may be missed. If cystic fibrosis is suspected, a sweat test is still indicated as to not miss diagnosing this serious illness.